Integrating clinical and economic outcomes in the elderly myeloma management: a comparative cost-effectiveness analysis
Frontiers in Oncology · 24.08.2026 · 16
DOI: 10.3389/fonc.2026.1774263 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 24.08.2026. Verfasst von Antonio G Solimando und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), Unit of Internal Medicine 'Guido Baccelli', University of Bari Aldo Mo…. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Multiple myeloma (MM) is a hematologic malignancy that predominantly affects older adults and poses substantial therapeutic challenges due to the high prevalence of comorbidities and limited treatment tolerability. This study evaluates the cost-effectiveness of four first-line treatment regimens for elderly MM patients, ineligible for autologous stem cell transplantation (ASCT): bortezomib, melphalan, and prednisone (VMP); daratumumab in combination with VMP (D-VMP); lenalidomide and dexamethasone (Rd); and daratumumab combined with Rd (DARA-Rd).
Methods
A state-transition Markov model was developed, with transition probabilities parameterized using data derived from the pivotal ALCYONE and MAIA clinical trials. Cost-effectiveness was assessed from the perspective of the Italian National Health Service using a state-transition model comparing VMP, D-VMP, Rd and DARA-Rd over a 5.25-year horizon. Probabilistic sensitivity analyses (PSA) were conducted to account for parameter uncertainty and summarized through cost-effectiveness acceptability curves (CEACs).
Results
Rd generated 1.53 QALYs for €60,483, whereas D-VMP generated 1.70 QALYs at €88,331, resulting in an ICER of €160,804/QALY. DARA-Rd and VMP were dominated.
Conclusion
The findings indicate that Rd is the strategy with the highest probability of being cost-effective at willingness-to-pay (WTP) thresholds below €250,000 per quality-adjusted life year (QALY) gained. Conversely, for WTP thresholds exceeding €250,000 per QALY gained, D-VMP emerges as the preferred option, offering the most favorable balance between additional costs and health benefits.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), Unit of Internal Medicine 'Guido Baccelli', University of Bari Aldo Moro Medical School, Bari, Italy.
- Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), Section of Pharmacology, University of Bari Aldo Moro Medical School, Bari, Italy.
- Allergology and Clinical Immunology Medical Specialty School, University of Bari Aldo Moro Medical School, Bari, Italy.
- Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), CITEL Telemedicine Research Center, University of Bari Aldo Moro, Bari, Italy.
Zitieren
APA
Solimando, A. G., Desantis, V., Di Marzo, L., de Martino, G., D'Amore, S., Girardi, L., Dicuonzo, G., Andriano, A., Dammacco, F., Vacca, A., Bilancia, M., & Ria, R. (2026). Integrating clinical and economic outcomes in the elderly myeloma management: a comparative cost-effectiveness analysis. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1774263
Vancouver
Solimando AG, Desantis V, Di Marzo L, de Martino G, D'Amore S, Girardi L, et al. Integrating clinical and economic outcomes in the elderly myeloma management: a comparative cost-effectiveness analysis. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1774263
BibTeX
@article{Solimando2026,
author = {Solimando, Antonio G and Desantis, Vanessa and Di Marzo, Lucia and de Martino, Giulia and D'Amore, Simona and Girardi, Leonardo and Dicuonzo, Giuseppe and Andriano, Alessandro and Dammacco, Franco and Vacca, Angelo and Bilancia, Massimo and Ria, Roberto},
title = {Integrating clinical and economic outcomes in the elderly myeloma management: a comparative cost-effectiveness analysis},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1774263}
}
EUVIMED